Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.
News & Analysis: Biogen
Pfizer could be only the first of several to spend billions buying smaller biotech.
Which of these elite biotechs is the better buy right now?
First-quarter sales were up 11%, but future growth is less certain.
BIIB earnings call for the period ending March 31, 2019.
These two drug stocks have been the industry's biggest losers this year. Which is the better buy now?
Sometimes opportunity comes in the shape of trouble.
Which stock wins in a battle of two big biotechs?
The biotech giant's most important drug is under a microscope and it doesn't look pretty.
The drugmaker has $4.9 billion in the bank.